Special Workgroups

High-Sensitivity Troponin

The FDA recently approved the first "high-sensitivity troponin" assay for use in the U.S., and we have received a few requests for LOINC codes from manufacturers of these tests. High-sensitivity troponin tests detect significantly lower levels of troponin than conventional assays, but they vary in their limits of detection by more than 100-fold across manufacturers (e.g., 10 ng/L versus 0.1 ng/L). Current guidelines (e.g., European Society for Cardiology) recommend using manufacturer assay-specific cutoffs when interpreting the results.

Existing LOINC codes have Methods such as "Detection limit less than..." and "High sensitivity", but neither of these by itself provides enough information unless we create "Detection limit" codes with exact assay-specific limits, which would not be consistent with our current convention, which is to have different detection limit Methods to represent 10-fold differences, but not the exact assay-specific limit.

The task for this Workgroup is to review the key points of the high-sensitivity troponin assays and published guidelines about how to report and interpret their results, and develop a recommendation for how best to model these terms in LOINC.

Recommendations made at December 2017 Committee Meeting.

Swapna Abhyankar (Regenstrief)
Salve Achacoso (Independent)
Sara Armson (Regenstrief)
Donna Armstrong (Evangelical Community Hospital)
Dannita Brooker (Sanofi)
Lorie Carey (CHI)
Jami Deckard (Regenstrief)
Xavier Gansel (bioMerieux)
Catherine Holck (JP Systems)
Francoise Holder (bioMerieux)
Charles McDonald (Cerner)
Robert Moser (St. Francis Medical)
Andrea Pitkus (IMO)
Lisa Thomas (eHealth Ontario)
Steiner Voigt (Regenstrief)
Mary Zabriskie (Regenstrief)

LOINC Better Names

LOINC users lack guidance on what observation name to use when storing and exchanging data when systems cannot conform to the recommended guidance from HL7 and LOINC. The task for this Workgroup is to develop a proposal that includes recommendations and a potential solution for an alternate name when none of the existing names in LOINC are suitable.

Recommendations made at December 2017 Committee Meeting.

Swapna Abhyankar (Regenstrief)
Salve Achacoso (Independent)
Donna Armstrong (Evangelical Community Hospital)
Dannita Brooker (Sanofi)
Lorie Carey (CHI)
Jami Deckard (Regenstrief)
Robert Dieterle (EnableCare)
MariBeth Gagnon (CDC)
Tina Hardin (JMC Consulting)
Leanna Harmon (LabCorp)
Barbara Herrmann (Mayo)
Catherine Holck (JP Systems)
John Hook (Regenstrief)
Stan Huff (Intermountain)
Alec Johnson (Cerner)
Madhavi Khamar (ABC)
Carolyn Knapik (CAP)

Stephanie Lipow (NLM)
Rosemary Malone (Leidos Health)
Charles McDonald (Cerner)
Clement McDonald (NLM)
Graylin Mitchell (CDC)
Anil Patel (eHealth Ontario)
Andrea Pitkus (IMO)
Anna Pron-Zwick (AstraZeneca)
Rita Pyle (eHealth Ontario)
Jacqueline Rosario (VA Boston)
John Snyder (Geisinger)
Sonya Strider (CDC)
Lisa Thomas (eHealth Ontario)
Steiner Voigt (Regenstrief)
Daniel Vreeman (Regenstrief)
Juliette Wyatt (PAML)
Joseph Yao (Mayo)
Mary Zabriskie (Regenstrief)

Gene Targets

This special topics workgroup is focused on determining the level of specificity needed in a LOINC term to distinguish nucleic acid-based tests for microorganism identification. The group will develop a proposal for the extent to which the nucleic acid target should be specified in the LOINC Component for different contexts as well as recommendations for mapping.

Recommendations made at June 2017 Committee Meeting.

Swapna Abhyankar (Regenstrief)
Pam Banning (3M)
Lori Carey (CHI)
Zac Danielson (Epic)
Jami Deckard (Regenstrief)
Xavier Gansel (Biomerieux)
Chris Gordon (3M)
Leanna Harmon (LabCorp)
Barbara Herrmann (Mayo)
Katy Holck (JP Systems)
Cindy Johns (LabCorp)
Mark Jones (BAH)

Kiersten Kolz (Biofire)
Riki Merrick (APHL)
Sara Mulroy (Epic)
Brad Munsterteiger (Epic)
Swanand Patil (Epic)
Andrea Pitkus (IMO)
Eric Rose (IMO)
Daniel Rutz (Epic)
Si Yuan Shen (Epic)
John Snyder (Geisinger)
Joseph Yao (Mayo)
Mary Zabriskie (Regenstrief)

System for Genetic Testing

The purpose of the special topics workgroup on the LOINC system for genetic testing is to develop a proposal regarding the level of granularity necessary in the System part of LOINC codes in different domains of genetic testing, including germline versus somatic, in order to clarify the usage of existing codes and develop guidelines for determining whether new codes are necessary going forward.

Recommendations made at June 2017 Committee Meeting.

Swapna Abhyankar (Regenstrief)
Pam Banning (3M)
Lori Carey (CHI)
Zac Danielson (Epic)
Jami Deckard (Regenstrief)
Xavier Gansel (Biomerieux)
Chris Gordon (3M)
Leanna Harmon (LabCorp)
Barbara Herrmann (Mayo)
Katy Holck (JP Systems)
Cindy Johns (LabCorp)

Mark Jones (BAH)
Sue Korsak (Regenstrief)
Riki Merrick (APHL)
Sarah Mulroy (Epic)
Brad Munsterteiger (Epic)
Swanand Patil (Epic)
Andrea Pitkus (IMO)
Eric Rose (IMO)
Dan Rutz (Epic)
Si Yuan Shen (Epic)
John Snyder (Geisinger)

PCR-Based Methods

The purpose of the PCR-based methods special topics workgroup is to review all of the existing nucleic acid testing methods in LOINC and develop a proposal regarding at what level of granularity these methods need to be distinguished and how best to name them.

Recommendations made at June 2017 Committee Meeting.

Swapna Abhyankar (Regenstrief)
Pam Banning (3M)
Lori Carey (CHI)
Zac Danielson (Epic)
Jami Deckard (Regenstrief)
Xavier Gansel (Biomerieux)
Chris Gordon (3M)
Cindy Johns (LabCorp)
Mark Jones (BAH)
Leanna Harmon (LabCorp)
Barbara Herrmann (Mayo)
Kiersten Kolz (Biofire)

Riki Merrick (APHL)
Sara Mulroy (Epic)
Brad Munsterteiger (Epic)
Swanand Patil (Epic)
Andrea Pitkus (IMO)
Eric Rose (IMO)
Dan Rutz (Epic)
Si Yuan Shen (Epic)
John Snyder (Geisinger)
Steiner Voigt (Regenstrief)
Joseph Yao (Mayo)